WHF Position Statement on COVID Vaccination

F Thienemann, G Chakafana, D Piñeiro, F J Pinto, P Perel, K Singh, J-L Eiselé, D Prabhakaran, K Sliwa, F Thienemann, G Chakafana, D Piñeiro, F J Pinto, P Perel, K Singh, J-L Eiselé, D Prabhakaran, K Sliwa

Abstract

The current COVID-19 pandemic has challenged health systems and communities globally. As such, several countries have embarked on national COVID-19 vaccination programmes in order to curb spread of the disease. However, at present, there isn't yet enough dosages to enable vaccination of the general population. Different vaccine prioritization strategies are thus being implemented in different communities in order to permit for a systematic vaccination of individuals. Here, on behalf of the World Heart Federation, we emphasize the need for individuals with Cardiovascular disease to be prioritized in national vaccine prioritization programmes as these are high risk individuals.

Keywords: COVID vaccination; cardiovascular disease; global health.

Conflict of interest statement

The authors have no competing interests to declare.

Copyright: © 2021 The Author(s).

Figures

Figure 1
Figure 1
Landscape of COVID-19 vaccines. (A) Several vaccines are in the production pipeline at several development stages. (B) Although different approaches are being employed in the development of COVID-19 vaccines, many of the vaccines currently undergoing clinical trials are subunit and vector-based vaccines. (C) The global distribution of COVID-19 vaccine recipients as at 22 February 2021. Data source: Covid-19 Vaccine Tracker Updates: The Latest – The New York Times (nytimes.com); COVID19 Vaccine Tracker (trackvaccines.org); https://ourworldindata.org/covid-vaccinations.
Figure 2
Figure 2
Distribution of CVD risk factors in COVID-19 mortality. (A) CVD and hypertension are responsible for most of COVID-19 related mortalities. (B) Hypertension is a major contributor to COVID-19 mortality. Data sourced from study by Li et al., 2020 [19].
Figure 3
Figure 3
Outcomes of COVID-19 infection in CVD patients.

References

    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. .
    1. V’Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat Rev Microbiol. 2021; 19: 155–170. DOI: 10.1038/s41579-020-00468-6
    1. Wang N, Shang J, Jiang S, Du L. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Front Microbiol. 2020; 11: 298. DOI: 10.3389/fmicb.2020.00298
    1. Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: A road ahead. Indian J Med Res. 2013; 138: 779–795.
    1. Forni G, Mantovani A, Covid-19 Commission of Accademia Nazionale dei Lincei R. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ. 2021. DOI: 10.1038/s41418-020-00720-9
    1. Times. TNY. Covid-19 Vaccine Tracker Updates: The Latest nytimescom 2021; Sect. .
    1. .
    1. Liu MA. Immunologic basis of vaccine vectors. Immunity. 2010; 33: 504–515. DOI: 10.1016/j.immuni.2010.10.004
    1. CDC Report. Emerging SARS-CoV-2 Variants .
    1. Tang JW, Toovey OTR, Harvey KN, Hui DDS. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J Infect. 2021. DOI: 10.1016/j.jinf.2021.01.007
    1. Iwata-Yoshikawa N, Uda A, Suzuki T, et al. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. 2014; 88: 8597–8614. DOI: 10.1128/JVI.00983-14
    1. Baden LR, El Sahly HM, Essink B, et al.Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021; 384: 403–416. DOI: 10.1056/NEJMoa2035389
    1. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England journal of medicine. 2020; 383: 2439–2450. DOI: 10.1056/NEJMoa2027906
    1. Perricone C, Triggianese P, Bartoloni E, et al.The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020; 111: 102468. DOI: 10.1016/j.jaut.2020.102468
    1. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020; 141: 1648–1655. DOI: 10.1161/CIRCULATIONAHA.120.046941
    1. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. Journal of the American College of Cardiology. 2020; 75: 2352–2371. DOI: 10.1016/j.jacc.2020.03.031
    1. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA cardiology. 2020; 5: 831–840. DOI: 10.1001/jamacardio.2020.1286
    1. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine. 2020; 180: 934–943. DOI: 10.1001/jamainternmed.2020.0994
    1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine. 2020; 382: 1199–1207. DOI: 10.1056/NEJMoa2001316
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395: 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3
    1. Roth GA, Johnson C, Abajobir A, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology. 2017; 70: 1–25. DOI: 10.1016/j.jacc.2017.04.052
    1. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020; 7: 11. DOI: 10.1186/s40779-020-00240-0
    1. Bohm M, Frey N, Giannitsis E, Sliwa K, Zeiher AM. Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: Expert document from the German Cardiac Society and the World Heart Federation. Clinical research in cardiology: Official journal of the German Cardiac Society. 2020; 109: 1446–1459. DOI: 10.1007/s00392-020-01656-3
    1. Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci U S A. 2008; 105: 7809–7814. DOI: 10.1073/pnas.0711241105
    1. Grover SP, Mackman N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arterioscler Thromb Vasc Biol. 2018; 38: 709–725. DOI: 10.1161/ATVBAHA.117.309846
    1. Glowacka I, Bertram S, Herzog P, et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol. 2010; 84: 1198–1205. DOI: 10.1128/JVI.01248-09
    1. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126: 1456–1474. DOI: 10.1161/CIRCRESAHA.120.317015
    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. The Lancet. Respiratory medicine. 2020; 8: 475–481. DOI: 10.1016/S2213-2600(20)30079-5
    1. Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: A case report and insights. Infection. 2020; 48: 773–777. DOI: 10.1007/s15010-020-01424-5
    1. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat Rev Endocrinol. 2021; 17: 11–30. DOI: 10.1038/s41574-020-00435-4
    1. Radder RS, Quinn AE, Georges A, Sarre SD, Shine R. Genetic evidence for co-occurrence of chromosomal and thermal sex-determining systems in a lizard. Biol Lett. 2008; 4: 176–178. DOI: 10.1098/rsbl.2007.0583
    1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. The New England journal of medicine. 2013; 368: 2004–2013. DOI: 10.1056/NEJMra1216063
    1. Chakafana G, Mutithu D, Hoevelmann J, Ntusi N, Sliwa K. Interplay of COVID-19 and cardiovascular diseases in Africa: An observational snapshot. Clinical research in cardiology: Official journal of the German Cardiac Society. 2020; 109: 1460–1468. DOI: 10.1007/s00392-020-01720-y
    1. Magadum A, Kishore R. Cardiovascular Manifestations of COVID-19 Infection. Cells. 2020; 9; 2508. DOI: 10.3390/cells9112508
    1. Armstrong SM, Wang C, Tigdi J, et al. Influenza infects lung microvascular endothelium leading to microvascular leak: Role of apoptosis and claudin-5. PloS one. 2012; 7: e47323. DOI: 10.1371/journal.pone.0047323
    1. Pothineni NVK, Subramany S, Kuriakose K, et al. Infections, atherosclerosis, and coronary heart disease. European heart journal. 2017; 38: 3195–3201. DOI: 10.1093/eurheartj/ehx362
    1. Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care. 2008; 31(Suppl 2): S185–189. DOI: 10.2337/dc08-s246
    1. World Health Organization. Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID-19 developed by Oxford University and AstraZeneca. .
    1. COVAX Explained.
    1. Mallapaty S. Vaccines are curbing COVID: Data from Israel show drop in infections. Nature. 2021; 590: 197. DOI: 10.1038/d41586-021-00316-4.
    1. Petter E, Mor O, Zuckerman N, et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. 2021. .
    1. ; .
    1. CDC Covid Data Tracker. 2021. .
    1. Rampini SK, Wolfensberger A, Sax H, Thienemann F. Preventing intrahospital transmission of COVID-19: Experience from the University Hospital Zurich in Switzerland. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2020; 110: 709–710.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel